TCIM
XLRN

TIAA CREF Investment Management’s Acceleron Pharma XLRN Stock Holding History

TIAA CREF Investment Management’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$3.94M Sell
84,655
-34,175
-29% -$1.5M ﹤0.01% 1594
2018
Q4 		$5.17M Sell
118,830
-1,954
-2% -$97.6K ﹤0.01% 1353
2018
Q3 		$6.91M Buy
120,784
+17,986
+17% +$884K ﹤0.01% 1356
2018
Q2 		$4.99M Buy
102,798
+15,987
+18% +$582K ﹤0.01% 1599
2018
Q1 		$3.39M Sell
86,811
-216
-0.2% -$9.18K ﹤0.01% 1806
2017
Q4 		$3.69M Buy
87,027
+3,178
+4% +$119K ﹤0.01% 1793
2017
Q3 		$3.13M Sell
83,849
-2,362
-3% -$82K ﹤0.01% 1904
2017
Q2 		$2.62M Sell
86,211
-12,532
-13% -$363K ﹤0.01% 2023
2017
Q1 		$2.61M Buy
98,743
+20,189
+26% +$532K ﹤0.01% 1971
2016
Q4 		$2M Sell
78,554
-5,142
-6% -$163K ﹤0.01% 2191
2016
Q3 		$3.03K Sell
83,696
-16,496
-16% -$546K ﹤0.01% 1923
2016
Q2 		$3.4M Buy
100,192
+10,605
+12% +$345K ﹤0.01% 1801
2016
Q1 		$2.36M Buy
89,587
+20,263
+29% +$589K ﹤0.01% 1976
2015
Q4 		$3.38M Sell
69,324
-2,009
-3% -$72.3K ﹤0.01% 1823
2015
Q3 		$1.78M Sell
71,333
-1,726
-2% -$51.9K ﹤0.01% 2222
2015
Q2 		$2.31M Buy
73,059
+15,653
+27% +$505K ﹤0.01% 2211
2015
Q1 		$2.19M Hold
57,406
– – ﹤0.01% 2166
2014
Q4 		$2.24M Sell
57,406
-2,782
-5% -$97K ﹤0.01% 2164
2014
Q3 		$1.82M Sell
60,188
-13,327
-18% -$375K ﹤0.01% 2281
2014
Q2 		$2.5M Buy
73,515
+36,374
+98% +$1.22M ﹤0.01% 2168
2014
Q1 		$1.28M Sell
37,141
-11,929
-24% -$538K ﹤0.01% 2499
2013
Q4 		$1.94M Buy
+49,070
New +$1.18M ﹤0.01% 2273

Other funds holding XLRN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

TIAA CREF Investment Management's XLRN Position: Q1 2019 in Review

TIAA CREF Investment Management reduced its Acceleron Pharma (XLRN) stake by 29% in Q1 2019, selling an estimated $1.5M and leaving 84,655 shares worth $3.94M. The position accounts for ﹤0.01% of the portfolio, ranked #1594.

TIAA CREF Investment Management first reported a position in XLRN in Q4 2013 and has held it in 22 quarters since. The position peaked at $6.91M in Q3 2018. 171 funds tracked by Wall St. Rank hold XLRN as of Q1 2019.

  • TIAA CREF Investment Management held 84,655 shares of Acceleron Pharma worth $3.94M as of Q1 2019.
  • TIAA CREF Investment Management sold 34,175 Acceleron Pharma shares in Q1 2019, an estimated $1.5M.
  • Acceleron Pharma made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #1594 holding.
  • TIAA CREF Investment Management first reported a position in Acceleron Pharma in Q4 2013 and has held it in 22 quarters since.
  • TIAA CREF Investment Management's Acceleron Pharma position peaked at $6.91M in Q3 2018.
  • 171 funds tracked by Wall St. Rank held Acceleron Pharma as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.